Latest Commercialisation News

Chimeric Therapeutics has received a $4.5 million R&D tax incentive refund from the Australian Government, underscoring its ongoing investment in innovative cancer cell therapies.

Wide Open Agriculture has received a $586,624 tax rebate for its overseas research activities in Germany, supporting the commercialisation of its proprietary lupin protein products.

Chariot Corporation and partners have formalized a phased small-scale mining initiative in Nigeria, aiming to unlock near-term lithium production while advancing larger exploration goals.

Cynata Therapeutics has completed the final patient visit in its Phase 3 trial for CYP-004, targeting knee osteoarthritis, with results expected in mid-2026. This milestone advances hopes for a disease-modifying therapy in a market desperate for new options.

ClearVue Technologies has secured an A$881k Australian Government R&D rebate and used part of it to retire a A$409k loan, strengthening its financial position as it advances its solar glass technology.

New data reveals that Thoroughbred racehorses free from oxidative stress are significantly more likely to win or place, spotlighting OxiDx’s patented biomarker test as a game-changer in equine performance and welfare.

IRIS Metals has partnered with Rock Zero to pioneer a low-emission lithium refining process in the U.S., aiming to secure a domestic supply chain with breakthrough technology.

Altech Batteries has secured a strategic collaboration with a leading global battery manufacturer to evaluate its breakthrough Silumina Anodes™ silicon-enhanced technology, marking a significant step toward commercialisation.

LaserBond’s 2025 AGM reveals a pivotal CEO transition alongside a strong financial rebound driven by strategic investments and technology licensing deals.

Ava Risk Group announces the upcoming retirement of CEO Mal Maginnis, with senior executive Neville Joyce appointed as Acting CEO. The company embarks on a global search for a permanent replacement amid strong recent growth.

Orthocell Limited reports growing adoption of its Remplir™ nerve repair product in nerve-sparing prostate cancer surgeries across Australia, positioning for a significant U.S. market expansion. The company is investing in research and commercial infrastructure ahead of a medium-term U.S. launch.

Independent testing by UNSW confirms Green Critical Minerals’ Very High Density (VHD) technology outperforms copper and aluminium in thermal conductivity and diffusivity, positioning it as a breakthrough in thermal management.